Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study.
Adult
Aged
Aged, 80 and over
Biomarkers
/ cerebrospinal fluid
Depressive Disorder, Major
/ cerebrospinal fluid
Electroconvulsive Therapy
Endocannabinoids
/ cerebrospinal fluid
Female
Glucuronidase
/ cerebrospinal fluid
Humans
Immunity, Innate
Klotho Proteins
Male
Middle Aged
Nerve Degeneration
/ cerebrospinal fluid
Sphingolipids
/ cerebrospinal fluid
Treatment Outcome
Young Adult
Biomarker
Cerebrospinal fluid
Depression
Electroconvulsive therapy
Journal
Neuropsychobiology
ISSN: 1423-0224
Titre abrégé: Neuropsychobiology
Pays: Switzerland
ID NLM: 7512895
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
05
2018
accepted:
21
06
2018
pubmed:
20
8
2018
medline:
12
12
2018
entrez:
20
8
2018
Statut:
ppublish
Résumé
No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. The sample size is small and the -distribution of responders and non-responders is uneven. It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.
Sections du résumé
BACKGROUND
BACKGROUND
No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet.
METHOD
METHODS
Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT.
RESULTS
RESULTS
Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level.
LIMITATIONS
CONCLUSIONS
The sample size is small and the -distribution of responders and non-responders is uneven.
CONCLUSIONS
CONCLUSIONS
It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.
Identifiants
pubmed: 30121652
pii: 000491401
doi: 10.1159/000491401
doi:
Substances chimiques
Biomarkers
0
Endocannabinoids
0
Sphingolipids
0
Glucuronidase
EC 3.2.1.31
Klotho Proteins
EC 3.2.1.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-22Informations de copyright
© 2018 S. Karger AG, Basel.